Bendahhou S, Cummins T R, Hahn A F, Langlois S, Waxman S G, Ptácek L J
Howard Hughes Medical Institute, Eccles Institute of Human Genetics, University of Utah, Salt Lake City, Utah 84112, USA.
J Clin Invest. 2000 Aug;106(3):431-8. doi: 10.1172/JCI9654.
Hyperkalemic periodic paralysis (HyperKPP) is an autosomal dominant skeletal muscle disorder caused by single mutations in the SCN4A gene, encoding the human skeletal muscle voltage-gated Na(+) channel. We have now identified one allele with two novel mutations occurring simultaneously in the SCN4A gene. These mutations are found in two distinct families that had symptoms of periodic paralysis and malignant hyperthermia susceptibility. The two nucleotide transitions predict phenylalanine 1490-->leucine and methionine 1493-->isoleucine changes located in the transmembrane segment S5 in the fourth repeat of the alpha-subunit Na(+) channel. Surprisingly, this mutation did not affect fast inactivation parameters. The only defect produced by the double mutant (F1490L-M1493I, expressed in human embryonic kidney 293 cells) is an enhancement of slow inactivation, a unique behavior not seen in the 24 other disease-causing mutations. The behavior observed in these mutant channels demonstrates that manifestation of HyperKPP does not necessarily require disruption of slow inactivation. Our findings may also shed light on the molecular determinants and mechanism of Na(+) channel slow inactivation and help clarify the relationship between Na(+) channel defects and the long-term paralytic attacks experienced by patients with HyperKPP.
高钾性周期性麻痹(HyperKPP)是一种常染色体显性遗传性骨骼肌疾病,由编码人类骨骼肌电压门控性钠通道的SCN4A基因发生单基因突变所致。我们现已在SCN4A基因中鉴定出一个同时发生两个新突变的等位基因。这些突变出现在两个不同的家族中,这两个家族均有周期性麻痹症状和恶性高热易感性。这两个核苷酸转换预测位于α亚基钠通道第四个重复序列的跨膜片段S5中的苯丙氨酸1490变为亮氨酸以及甲硫氨酸1493变为异亮氨酸。令人惊讶的是,这种突变并未影响快速失活参数。双突变体(F1490L-M1493I,在人胚肾293细胞中表达)产生的唯一缺陷是慢失活增强,这是在其他24种致病突变中未见过的独特表现。在这些突变通道中观察到的行为表明,高钾性周期性麻痹的表现不一定需要慢失活的破坏。我们的发现也可能有助于揭示钠通道慢失活的分子决定因素和机制,并有助于阐明钠通道缺陷与高钾性周期性麻痹患者长期麻痹发作之间的关系。